Waters Parkerson & CO. LLC Has $30.64 Million Position in Merck & Co., Inc. (NYSE:MRK)

Waters Parkerson & CO. LLC lifted its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 1.9% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 308,022 shares of the company's stock after purchasing an additional 5,743 shares during the quarter. Merck & Co., Inc. accounts for 1.6% of Waters Parkerson & CO. LLC's investment portfolio, making the stock its 19th largest holding. Waters Parkerson & CO. LLC's holdings in Merck & Co., Inc. were worth $30,642,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of MRK. Midwest Capital Advisors LLC purchased a new stake in shares of Merck & Co., Inc. during the fourth quarter worth about $26,000. Financial Life Planners bought a new position in Merck & Co., Inc. in the 4th quarter valued at approximately $28,000. Noble Wealth Management PBC bought a new stake in Merck & Co., Inc. in the 4th quarter worth about $28,000. Halbert Hargrove Global Advisors LLC bought a new position in shares of Merck & Co., Inc. during the 4th quarter valued at $28,000. Finally, Promus Capital LLC purchased a new position in shares of Merck & Co., Inc. in the fourth quarter worth approximately $30,000. Institutional investors and hedge funds own 76.07% of the company's stock.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, SVP Dalton E. Smart III sold 4,262 shares of the firm's stock in a transaction on Friday, April 25th. The shares were sold at an average price of $82.76, for a total value of $352,723.12. Following the completion of the sale, the senior vice president now directly owns 7,778 shares in the company, valued at approximately $643,707.28. This trade represents a 35.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.13% of the company's stock.

Merck & Co., Inc. Stock Up 1.7%

MRK stock opened at $76.08 on Monday. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.36 and a quick ratio of 1.15. The business's fifty day moving average price is $83.46 and its two-hundred day moving average price is $92.17. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $134.63. The stock has a market capitalization of $191.03 billion, a price-to-earnings ratio of 11.30, a PEG ratio of 0.77 and a beta of 0.43.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its earnings results on Thursday, April 24th. The company reported $2.22 EPS for the quarter, topping the consensus estimate of $2.16 by $0.06. The company had revenue of $15.53 billion for the quarter, compared to analysts' expectations of $15.59 billion. Merck & Co., Inc. had a net margin of 26.67% and a return on equity of 45.35%. The business's revenue for the quarter was down 1.6% on a year-over-year basis. During the same period last year, the firm earned $2.07 earnings per share. On average, equities analysts anticipate that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. announced that its Board of Directors has approved a share repurchase plan on Tuesday, January 28th that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the company to repurchase up to 4.1% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's board of directors believes its stock is undervalued.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Guggenheim reissued a "buy" rating and set a $115.00 target price on shares of Merck & Co., Inc. in a research note on Thursday, April 17th. Deutsche Bank Aktiengesellschaft cut Merck & Co., Inc. from a "buy" rating to a "hold" rating and cut their target price for the company from $128.00 to $105.00 in a research note on Tuesday, February 18th. Citigroup restated a "neutral" rating and issued a $84.00 target price (down from $115.00) on shares of Merck & Co., Inc. in a research note on Wednesday, May 14th. TD Securities cut shares of Merck & Co., Inc. from a "buy" rating to a "hold" rating and lowered their price target for the stock from $121.00 to $100.00 in a research report on Monday, February 10th. Finally, Bank of America dropped their target price on Merck & Co., Inc. from $118.00 to $112.00 and set a "buy" rating on the stock in a research note on Wednesday, February 5th. Thirteen analysts have rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, Merck & Co., Inc. has a consensus rating of "Moderate Buy" and a consensus target price of $109.19.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.